Amino acid decarboxylases are a class of enzymes that catalyze the removal of the carboxyl group from specific amino acids to produce biologically active amines. These enzymes are widely involved in various physiological processes, particularly in the synthesis of neurotransmitters and polyamines. Aromatic L-amino acid decarboxylase (AADC), histidine decarboxylase (HDC), and S-adenosylmethionine decarboxylase (SAMDC) all belong to the amino acid decarboxylase family, each playing an important role in different metabolic pathways to regulate cellular functions.
AADC is primarily responsible for converting aromatic amino acid precursors l-DOPA and 5-hydroxytryptophan into the neurotransmitters dopamine and serotonin. These neurotransmitters are crucial for the normal functioning of the brain, and AADC deficiency leads to severe neurological disorders, including motor dysfunction, autonomic nervous system dysfunction, and behavioral abnormalities.
HDC catalyzes the conversion of histidine to histamine. Histamine is an important mediator in allergic and inflammatory reactions, and a deficiency in HDC is closely related to immune dysfunction and allergic symptoms. For example, in some chronic inflammation and allergic reactions, the upregulation of HDC plays a crucial role in regulating histamine levels and immune cell function.
SAMDC is a key enzyme in the polyamine biosynthetic pathway, responsible for converting S-adenosylmethionine into decarboxylated S-adenosylmethionine, a precursor for the synthesis of spermidine and spermine. These polyamines play vital roles in cell growth, differentiation, and proliferation. The activity of SAMDC is closely related to the cellular concentration of polyamines, and SAMDC inhibitors are widely studied for anticancer and antiparasitic treatments.
Inhibitors targeting amino acid decarboxylases have potential applications in cancer and parasitic disease research. For example, since the polyamine biosynthetic pathway is upregulated in many tumors, SAMDC inhibitors can be used in cancer research, and SAMDC inhibitors are also important tools in antiparasitic research[1][2][3][4].
(Z)-Aconitic acid 是一种口服活性的谷氨酸脱羧酶 (glutamate decarboxylase) 抑制剂,可降低 IκB-α 磷酸化,并抑制抗原诱发的关节炎和 Monosodium urate (MS-E13881) 诱发的痛风。
Anti-GAD65 Antibody 是一种由 CHO 表达的人源抗体,靶向 GAD65,带有 huIgG1 型重链和 huλ 型轻链,预测分子量 (MW) 为 146.48 kDa,其同型对照可参考 Human IgG1 kappa, Isotype Control (MS-E04981)。
DL-Allylglycine(2-Aminopent-4-enoic acid)是一种谷氨酸脱羧酶(GAD)抑制剂,可显著增加小鼠脑内鸟氨酸脱羧酶(ODC)活性并降低 S-adenosyl-L-methionine 脱羧酶(SAM-DC)活性,导致大脑中 GABA 浓度显著下降,具有致痉挛活性,可用于研究诱导癫痫发作。
GAD65 (524-543) 是一种生物活性肽,其氨基酸序列为谷氨酸脱羧酶 65 (GAD65) 的 524 至 543 位氨基酸片段,是胰岛抗原中首批在自发性自身免疫性糖尿病非肥胖糖尿病 (NOD) 小鼠模型中诱导增殖性 T 细胞应答的片段之一,作为一种特异性刺激物可能对自发产生的致糖尿病 T 细胞克隆 BDC2.5 具有低亲和力,且用其免疫可增加 NOD 小鼠对 BDC2.5 T 细胞过继转移诱发的 1 型糖尿病的易感性。
GAD65 (524-543) acetate 是一种有生物活性的肽,其氨基酸序列为谷氨酸脱羧酶 65 (GAD65) 的 524 至 543 位氨基酸片段,是胰岛抗原中首批在自发性自身免疫性糖尿病非肥胖糖尿病 (NOD) 小鼠模型中诱导增殖性 T 细胞应答的片段之一,作为一种特异性刺激物可能对自发产生的致糖尿病 T 细胞克隆 BDC2.5 具有低亲和力,且用其免疫可增加 NOD 小鼠对 BDC2.5 T 细胞过继转移诱发的 1 型糖尿病的易感性。
L-Allylglycine(L-2-Allylglycine)是一种氨基酸衍生物,作为谷氨酸脱羧酶(glutamate decarboxylase,GAD)的抑制剂,可降低脑内 GABA 的生物合成,并具有致惊厥活性。
L-Allylglycine (L-2-Allylglycine) hydrochloride 是一种氨基酸衍生物,作为谷氨酸脱羧酶 (glutamate decarboxylase (GAD)) 的抑制剂,可降低脑内 GABA 的生物合成,并具有致惊厥活性。
属于裂解酶家族的L-Phenylalanine decarboxylase, Streptococcus faecalis (EC 4.1.1.53) 能够裂解碳-碳键,并参与苯丙氨酸的代谢,该酶有一个底物L-苯丙氨酸和两个产物苯乙胺和CO2。
Qc1 (Standard) 是 Qc1 (MS-K43749) 的分析标准品,可用于研究及分析应用,作为一种苏氨酸脱氢酶 (TDH) 抑制剂,Qc1 可用于研究代谢性疾病。